FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending October 31, 2008
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --


Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons



I give below details of changes in the interests of Directors, Persons Discharging Managerial Responsibility or Connected Persons in the 
Ordinary share
s of GlaxoSmithKline plc
 
in respect of the under
-
mentioned 
persons
 arising from the 
grant of 
options over 
Ordinary shares 
of 25
p each at a price of £9.51 per
 share pursuant t
o the GlaxoSmithKline UK Savings Related Share Option Plan 
("the Plan") on 23 October 2008:

Mr S M Bicknell
1,009
Mr E J Gray
1,009
Mr A S Hussain
1,009
Mr D Learmouth
1,009
Mr D 
S 
Redfern
1,009

Mr A Witty
1,009




The Company 
was 
advised of 
this information on 
31 October 
2008
.

This notification relates to a transac
tion notified in accordance with 
Disclosure 
and 
Transparency 
R
ule 3.1.4R(1)(a)
.


V A Whyte
Deputy 
Company Secretary

31
 October
 
2008

 

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: October 31, 2008

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc